KORU Medical Systems (NASDAQ:KRMD) Issues Earnings Results

KORU Medical Systems (NASDAQ:KRMD) announced its quarterly earnings data on Wednesday. The company reported ($0.02) EPS for the quarter, meeting analysts’ consensus estimates of ($0.02), Zacks reports. The company had revenue of $11.76 million during the quarter, compared to the consensus estimate of $11.28 million. KORU Medical Systems had a negative net margin of 5.27% and a negative return on equity of 13.61%.

Here are the key takeaways from KORU Medical Systems’ conference call:

• Q1 results beat expectations with $11.8M revenue (+22% YoY), adjusted EBITDA essentially break‑even (-$10k) and net loss improving 33% to $0.8M, while cash usage was minimal at $0.1M leaving $8.8M on the balance sheet.
• Management reiterated full‑year 2026 guidance of $47.5M–$50M revenue (15%–22% growth), 61%–63% gross margin, and positive adjusted EBITDA and cash flow, and retains access to a $10M debt facility.
• International expansion showed strong traction (international core +35%) driven by EU prefilled‑syringe conversions and distributor pump orders, supported by Freedom60 MDR clearance for prefilled syringe compatibility.
• The non‑IG pipeline advanced—now eight active non‑IG opportunities (>6M potential annual infusions), two pharma partners moved into phase III (including Apellis EMPAVELI in DGF), and a 510(k) was submitted for deferoxamine, while vancomycin was deprioritized.
• Q1 gross margin compressed to 61.5% (down 130 bps) due to production timing and tariff charges, although management says adjusted margins and cost initiatives keep full‑year margin guidance intact.

KORU Medical Systems Stock Performance

KRMD traded down $0.24 on Friday, reaching $4.20. The company had a trading volume of 146,690 shares, compared to its average volume of 120,097. The stock has a market cap of $192.91 million, a P/E ratio of -84.00 and a beta of 0.43. KORU Medical Systems has a fifty-two week low of $2.63 and a fifty-two week high of $6.61. The company’s fifty day moving average is $4.34 and its 200 day moving average is $4.85.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. B. Riley Financial raised their target price on shares of KORU Medical Systems from $7.00 to $8.00 and gave the company a “buy” rating in a research note on Friday, March 13th. Canaccord Genuity Group reissued a “buy” rating and set a $6.00 price target on shares of KORU Medical Systems in a research report on Friday, March 13th. Craig Hallum restated a “buy” rating and issued a $7.00 price objective on shares of KORU Medical Systems in a research note on Tuesday, January 13th. Wall Street Zen cut KORU Medical Systems from a “strong-buy” rating to a “buy” rating in a research report on Sunday, April 26th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of KORU Medical Systems in a research note on Tuesday, April 21st. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, KORU Medical Systems has an average rating of “Moderate Buy” and an average target price of $7.25.

Hedge Funds Weigh In On KORU Medical Systems

Institutional investors and hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC lifted its holdings in KORU Medical Systems by 1.6% during the 4th quarter. Geode Capital Management LLC now owns 1,022,860 shares of the company’s stock worth $5,944,000 after purchasing an additional 16,062 shares during the last quarter. Royal Bank of Canada boosted its stake in KORU Medical Systems by 8,719.9% in the 4th quarter. Royal Bank of Canada now owns 133,004 shares of the company’s stock valued at $773,000 after purchasing an additional 131,496 shares during the period. Goldman Sachs Group Inc. grew its holdings in KORU Medical Systems by 189.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 242,781 shares of the company’s stock valued at $617,000 after buying an additional 158,914 shares in the last quarter. Barclays PLC increased its position in KORU Medical Systems by 8.8% during the 4th quarter. Barclays PLC now owns 67,442 shares of the company’s stock worth $392,000 after buying an additional 5,457 shares during the period. Finally, Wells Fargo & Company MN increased its position in KORU Medical Systems by 78.1% during the 4th quarter. Wells Fargo & Company MN now owns 47,264 shares of the company’s stock worth $275,000 after buying an additional 20,720 shares during the period. Institutional investors and hedge funds own 58.60% of the company’s stock.

KORU Medical Systems Company Profile

KORU Medical Systems, Inc develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products.